SUBSCRIBE
SUBSCRIBE
News   Business

TransOral Pharmaceuticals, Inc. Swallows $23M Series C

October 31, 2005 | 
1 min read

Life science investors looking to mitigate their risk profile have shown confidence in TransOral Pharmaceuticals Inc. by investing $23 million in Series C financing as it teeters on the brink of late-stage clinical development.

Startups
MORE ON THIS TOPIC
AbbVie's office in South San Francisco, California
Obesity
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative background
Deals
BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal
February 28, 2025
 · 
2 min read
 · 
Annalee Armstrong
Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.
Layoffs
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
February 28, 2025
 · 
1 min read
 · 
Angela Gabriel
Pictured: Eli Lilly's headquarters in Indianapolis
Collaboration
Lilly Hops On Hot Molecular Glue Train With $1.2B+ Magnet Deal
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac